About Authors: Shoeib Afroz Mohammad,
M.Pharm (Pharmacology),
Vaagdevi College of Pharmacy, Kakatiya University
Reference ID: PHARMATUTOR-ART-1087
BACKGROUND:
By the 1930s, scientists had isolated and determined the structure of the steroid hormones and found that high doses of androgens, estrogens or progesterone inhibited ovulation. The first oral-contraceptive formulations marketed in the United States, in 1960 and1961, contained 2 to 5 times as much estrogen and 5 to 10 times as much progestin as the oral contraceptives now in use. Since introduced in May of 1960, these pills have provided reliable contracep¬tion for millions of woman throughout the world.They were given in a regimen consisting of 21 active tablets containing estrogen and progestin followed by 7 days of placebo tablets (21/7 regimen). The 7 days of placebo was designed for menses to occur during that time. The use of these high-dose formulations was linked to increased risks of ischemic stroke, myocardial infarction, and pulmonary embolism in healthy young women. The estrogen and progestin were reduced rapidly during the 1960s and 1970s because of concern about safety and because the reduction of the doses did not reduce the contraceptive effectiveness.The reductions in the dose of estrogen are believed to have decreased the risk of venous thrombosis. The combination estrogen–progestin oral contraceptives that are now on the market contain estrogen at doses ranging from 20 to 50 μg of ethinyl estradiol or, uncommonly, mestranol. Currently there are over 70 different brands on the market. 1
.gif)
Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia.
.png)
